SEOUL, South Korea, May 8, 2026
Rznomics announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to its lead investigational RNA-based therapeutic candidate, RZ-001, for the treatment of hepatocellular carcinoma (HCC), marking a significant regulatory milestone for the company’s proprietary RNA editing platform and strengthening its position within the rapidly evolving oncology gene therapy sector. The RMAT designation was awarded based on promising interim clinical findings from the ongoing Phase 1b/2a clinical study, including encouraging safety observations and preliminary anti-tumor activity demonstrated in patients with advanced liver cancer. The designation further validates Rznomics’ proprietary trans-splicing ribozyme-based RNA editing technology, which is designed to selectively replace cancer-driving RNA molecules with therapeutic RNA sequences in order to inhibit tumor progression while potentially improving treatment specificity and tolerability.
FDA RMAT Designation Strengthens Regulatory Pathway for RZ-001
The FDA’s RMAT program was established to accelerate the development and regulatory review of regenerative medicine therapies intended to treat serious or life-threatening diseases with high unmet medical need. Therapies receiving RMAT designation gain access to increased FDA guidance throughout development, opportunities for accelerated approval pathways, rolling review processes, and enhanced collaboration regarding clinical trial design, manufacturing strategy, and commercialization planning. According to Rznomics, the designation reflects growing regulatory recognition of RZ-001’s innovative mechanism and early clinical potential in hepatocellular carcinoma, one of the deadliest and most difficult-to-treat cancers globally. The company previously received both Orphan Drug Designation (ODD) in 2024 and Fast Track Designation (FTD) in 2025 for RZ-001 in HCC, further reinforcing the FDA’s continued support for accelerated development of the program.
RZ-001 represents a next-generation oncology therapeutic utilizing Rznomics’ proprietary RNA editing platform technology. Unlike traditional cancer therapies that focus on protein inhibition or immune modulation, RZ-001 uses a trans-splicing ribozyme mechanism to directly replace cancer-specific RNA transcripts with therapeutic RNA, enabling highly selective targeting of malignant cells while potentially minimizing damage to healthy tissue. The company believes this dual-action strategy may address limitations associated with existing therapies for advanced liver cancer, particularly in patients who experience resistance or inadequate responses to currently available treatments. Hepatocellular carcinoma remains a major global health burden with limited therapeutic options and poor long-term survival rates, especially in advanced-stage disease settings.
Early Phase 1b/2a Clinical Data Support Continued Development
Advertisement
The RMAT designation follows the presentation of interim clinical data from the ongoing Phase 1b/2a trial at the American Association for Cancer Research (AACR) Annual Meeting 2026, where Rznomics reported encouraging preliminary efficacy signals alongside a manageable safety profile. According to the company, the early data demonstrated evidence of anti-tumor activity in patients with advanced hepatocellular carcinoma, supporting continued clinical advancement of the therapy. Rznomics stated that the FDA’s decision highlights both the innovation of the platform and the potential clinical importance of RNA editing technologies within oncology drug development.
Company executives indicated that the RMAT designation will play an important role in accelerating global development efforts for RZ-001. Vice President Sung-woo Hong stated that the company intends to initiate formal discussions with the FDA regarding future clinical trial strategy, Chemistry, Manufacturing and Controls (CMC) requirements, and commercialization planning. Chief Executive Officer Seong-Wook Lee described the RMAT designation as a strong validation of the company’s RNA editing technology platform and emphasized Rznomics’ commitment to advancing the therapy toward potential global commercialization.
RNA Editing Therapies Continue Expanding in Oncology Development
The FDA’s decision also reflects increasing industry interest in RNA-based therapeutics and gene editing technologies as potential next-generation treatment approaches for cancer and rare diseases. While traditional gene therapies often focus on permanent DNA modification, RNA editing strategies offer the potential advantage of transient and highly targeted therapeutic intervention without directly altering the patient’s genome. Rznomics’ trans-splicing ribozyme platform represents one of several emerging RNA-focused technologies attempting to establish new therapeutic modalities across oncology and genetic disease applications.
As competition intensifies within the RNA therapeutics market, regulatory milestones such as RMAT designation can significantly accelerate development timelines and improve investor confidence for emerging biotechnology companies. For Rznomics, the advancement of RZ-001 into later-stage development could position the company among a growing group of innovators pursuing RNA editing-based cancer therapies aimed at addressing substantial unmet needs in difficult-to-treat solid tumors such as hepatocellular carcinoma.
Source: Rznomics press release
